AU2020904824A0 - Treatment for Coronavirus infection and associated cytokine toxicity (2) - Google Patents

Treatment for Coronavirus infection and associated cytokine toxicity (2)

Info

Publication number
AU2020904824A0
AU2020904824A0 AU2020904824A AU2020904824A AU2020904824A0 AU 2020904824 A0 AU2020904824 A0 AU 2020904824A0 AU 2020904824 A AU2020904824 A AU 2020904824A AU 2020904824 A AU2020904824 A AU 2020904824A AU 2020904824 A0 AU2020904824 A0 AU 2020904824A0
Authority
AU
Australia
Prior art keywords
treatment
coronavirus infection
associated cytokine
cytokine toxicity
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020904824A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2020904824A0 publication Critical patent/AU2020904824A0/en
Priority to PCT/AU2021/050215 priority Critical patent/WO2021179047A1/en
Priority to US17/910,220 priority patent/US20230120864A1/en
Priority to JP2022554820A priority patent/JP2023517239A/en
Priority to BR112022018200A priority patent/BR112022018200A2/en
Priority to EP21767048.8A priority patent/EP4117683A4/en
Priority to AU2021234945A priority patent/AU2021234945A1/en
Priority to CN202180031179.5A priority patent/CN115484964B/en
Priority to KR1020227035531A priority patent/KR20220159397A/en
Priority to CA3171235A priority patent/CA3171235A1/en
Priority to CL2022002457A priority patent/CL2022002457A1/en
Priority to US18/071,800 priority patent/US11938146B2/en
Abandoned legal-status Critical Current

Links

AU2020904824A 2020-03-12 2020-12-23 Treatment for Coronavirus infection and associated cytokine toxicity (2) Abandoned AU2020904824A0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA3171235A CA3171235A1 (en) 2020-03-12 2021-03-12 Treatment for coronavirus infection and associated cytokine toxicity
EP21767048.8A EP4117683A4 (en) 2020-03-12 2021-03-12 Treatment for coronavirus infection and associated cytokine toxicity
US17/910,220 US20230120864A1 (en) 2020-03-12 2021-03-12 Treatment for coronavirus infection and associated cytokine toxicity
JP2022554820A JP2023517239A (en) 2020-03-12 2021-03-12 Treatment of coronavirus infection and associated cytokine toxicity
BR112022018200A BR112022018200A2 (en) 2020-03-12 2021-03-12 TREATMENT FOR CORONAVIRUS INFECTION AND ASSOCIATED CYTOKINE TOXICITY
PCT/AU2021/050215 WO2021179047A1 (en) 2020-03-12 2021-03-12 Treatment for coronavirus infection and associated cytokine toxicity
AU2021234945A AU2021234945A1 (en) 2020-03-12 2021-03-12 Treatment for coronavirus infection and associated cytokine toxicity
CN202180031179.5A CN115484964B (en) 2020-03-12 2021-03-12 Treatment of coronavirus infection and associated cytokine toxicity
KR1020227035531A KR20220159397A (en) 2020-03-12 2021-03-12 Treatment for coronavirus infection and related cytokine toxicity
CL2022002457A CL2022002457A1 (en) 2020-03-12 2022-09-08 Treatment of coronavirus infection and cytokine-associated toxicity
US18/071,800 US11938146B2 (en) 2020-03-12 2022-11-30 Treatment for coronavirus infection and associated cytokine toxicity

Publications (1)

Publication Number Publication Date
AU2020904824A0 true AU2020904824A0 (en) 2021-01-21

Family

ID=

Similar Documents

Publication Publication Date Title
WO2021188969A3 (en) Coronavirus vaccines and methods of use
UA88463C2 (en) Pharmaceutical composition comprising compound i and method of treating hiv infection
WO2004024134A8 (en) Pharmaceutical formulations of modafinil
WO2005000878A3 (en) Compositions of lipopeptide antibiotic derivatives and methods of use thereof
NO20061468L (en) Use of tigecycline alone or in combination with rifampin for the treatment of osteomyelitis and / or septic arthritis
MX2022014561A (en) Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm.
IL277315B (en) Methods and composition for treating coronavirus infection
WO2022053993A3 (en) Treatments for sars-cov-2 infection (covid-19)
AU2020904824A0 (en) Treatment for Coronavirus infection and associated cytokine toxicity (2)
MX2022010920A (en) Pld for use in combination in the treatment of coronavirus.
AU2020900751A0 (en) Treatment for coronavirus infection and associated cytokine toxicity
EP4117683A4 (en) Treatment for coronavirus infection and associated cytokine toxicity
WO2023122260A3 (en) Inhibitors of sars-cov-2
WO2003061704A3 (en) Combination therapy for the treatment of bacterial infections
MX2023009041A (en) Use of proteasome inhibitors in the treatment of coronavirus infections.
EP4121038A4 (en) Compositions and methods for the treatment of coronavirus infection and respiratory compromise
MX2023008004A (en) Adenosine derivative and pharmaceutical composition comprising the same.
AU2020902150A0 (en) Coronavirus treatment (2)
AU2020902151A0 (en) Treatment of coronavirus (2)
DK1439840T3 (en) Antibacterial monobactam compounds and methods for their use
EP4009981A4 (en) Method and compositions for treating coronavirus infection
AU2021901169A0 (en) Novel compositions and methods for treating coronavirus infections
AU2022900358A0 (en) Novel compositions and methods for treating coronavirus infections
WO2005004880A8 (en) Vaginal compositions for treating pelvic tissue infections and traumas
WO2023003951A3 (en) Compositions and methods for the treatment of herpes simplex virus infection